Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Arsenic trioxide: an ancient drug revived.

Zhou J.

Chin Med J (Engl). 2012 Oct;125(19):3556-60. Review.

PMID:
23044323
2.

Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.

Lengfelder E, Hofmann WK, Nowak D.

Leukemia. 2012 Mar;26(3):433-42. doi: 10.1038/leu.2011.245. Epub 2011 Sep 9. Review.

PMID:
21904379
3.

[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].

Xu SN, Chen JP, Liu JP, Xia Y.

Zhong Xi Yi Jie He Xue Bao. 2009 Nov;7(11):1024-34. doi: 10.3736/jcim20091102. Review. Chinese.

4.

Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.

Bonati A, Rizzoli V, Lunghi P.

Curr Pharm Biotechnol. 2006 Dec;7(6):397-405. Review.

PMID:
17168655
5.

Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.

Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD.

Oncologist. 2002;7 Suppl 1:1-13. Review.

6.

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.

Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y, Liu X, Han X, Hu L, Wang S, Zhao Y, Zhang Y, Fan S, Lv C, Li L, Zhu L.

Blood. 2010 Mar 4;115(9):1697-702. doi: 10.1182/blood-2009-07-230805. Epub 2009 Dec 22.

7.

Expanding the use of arsenic trioxide: leukemias and beyond.

Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ.

Semin Hematol. 2002 Apr;39(2 Suppl 1):22-6. Review.

PMID:
12012319
8.

Arsenic trioxide.

Litzow MR.

Expert Opin Pharmacother. 2008 Jul;9(10):1773-85. doi: 10.1517/14656566.9.10.1773 . Review.

PMID:
18570609
9.

Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.

Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, Hu L, Wang S, Zhao Y, Li X, Zhang Y, Fan S, Lv C, Li Y, Su Y, Zhao H, Zhang X, Zhou J.

Cancer. 2013 Jan 1;119(1):115-25. doi: 10.1002/cncr.27650. Epub 2012 Aug 28.

10.
11.

[Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].

Jiao L, Wang SJ, Zhuang JL, Zhao YQ, Zhou DB, Xu Y, Han B, Zhang W, Duan MH, Zou N, Zhu TN, Shen T.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):555-8. Chinese.

12.

All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.

Quezada G, Kopp L, Estey E, Wells RJ.

Pediatr Blood Cancer. 2008 Jul;51(1):133-5. doi: 10.1002/pbc.21529.

PMID:
18293388
13.

Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.

Binet F, Antoine F, Girard D.

Inflamm Allergy Drug Targets. 2009 Mar;8(1):21-7. Review.

PMID:
19275690
15.

Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.

Sanz MA, Fenaux P, Lo Coco F; European APL Group of Experts.

Haematologica. 2005 Sep;90(9):1231-5. Review.

16.

Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.

Ninomiya M, Kajiguchi T, Yamamoto K, Kinoshita T, Emi N, Naoe T.

Haematologica. 2006 Nov;91(11):1571-2.

17.

Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.

Leu L, Mohassel L.

Am J Health Syst Pharm. 2009 Nov 1;66(21):1913-8. doi: 10.2146/ajhp080342.

PMID:
19850784
18.

Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.

Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M.

Curr Med Res Opin. 2005 Mar;21(3):403-11. Review.

PMID:
15811209
19.

How to manage acute promyelocytic leukemia.

Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z.

Leukemia. 2012 Aug;26(8):1743-51. doi: 10.1038/leu.2012.57. Epub 2012 Mar 16. Review.

PMID:
22422168
20.

What is the role of arsenic in newly diagnosed APL?

Tallman MS.

Best Pract Res Clin Haematol. 2008 Dec;21(4):659-66. doi: 10.1016/j.beha.2008.09.002. Review.

PMID:
19041605

Supplemental Content

Support Center